Aurinia Pharmaceuticals Inc.
Save
710.07M
Market cap
–
Current P/E
166.67x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Similar securities
Based on sector and market capitalization
Report issue